• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Eastern Mediterranean Health Journal: Al-Magallat al-Sihhiyyat li-Sarq al-Mutawassit >Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran
【24h】

Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran

机译：在伊朗伊斯兰共和国为5岁以下儿童引入肺炎球菌结合疫苗的成本效益

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background : Pneumococcal disease caused by Streptococcus pneumoniae results in considerable mortality and morbidity. Pneumococcal conjugate vaccines (PCV), such as PCV-13, can prevent invasive pneumococcal disease and avoid disability and death. The cost of introducing PCV-13 in childhood immunization schedules should be assessed against the cost of pneumococcal diseases for each community. Aims : This study aimed to evaluate the cost–effectiveness of introducing PCV-13 in the national immunization programme for children under 5 years in the Islamic Republic of Iran. Methods : The TRIVAC decision support model was used to estimate total costs of introducing PCV-13 and the disability-adjusted life years (DALYs) averted. The main pneumococcal diseases were considered—pneumonia, meningitis, acute otitis media, and non-pneumonia, non-meningitis infections—in terms of hospital admissions, outpatient visits and deaths. Local data were used to estimate costs. Results : Pneumococcal disease is estimated to affect 18 713 211 children under 5 years (519 412 pneumonia, 18 148 116 acute otitis media, 6884 meningitis, and 38 799 non-pneumonia, non-meningitis) in 10 years (2014–2023) without use of the vaccine. Introduction of PCV-13 would prevent 4 900 084 cases of pneumococcal disease (190 849 pneumonia, 4 692 450 acute otitis media, 2529 meningitis, and 14 256 non-pneumonia, non-meningitis). Pneumococcal infection would cause 287 950 hospital admissions and 29 399 deaths; vaccination could avert 105 802 hospital admissions and 9997 deaths. The incremental cost–effectiveness was estimated to be US$ 1890 and US$ 1538 per averted DALY for the government and society respectively. Conclusion : According to WHO-recommended thresholds for interpreting cost–effectiveness, introduction of PCV-13 for children under 5 years in the Islamic Republic of Iran would be cost-effective.
机译：背景：由肺炎链球菌引起的肺炎球菌疾病导致相当大的死亡率和发病率。肺炎球菌结合疫苗（PCV），例如PCV-13，可以预防侵袭性肺炎球菌疾病并避免致残和死亡。应对照每个社区的肺炎球菌疾病费用，评估在儿童免疫接种计划中引入PCV-13的费用。目的：本研究旨在评估在伊朗伊斯兰共和国针对5岁以下儿童的国家免疫规划中引入PCV-13的成本效益。方法：TRIVAC决策支持模型用于估算引入PCV-13的总成本以及避免的残疾调整生命年（DALYs）。考虑到主要的肺炎球菌疾病-肺炎，脑膜炎，急性中耳炎和非肺炎，非脑膜炎感染-从医院入院，门诊就诊和死亡方面考虑。当地数据被用来估算成本。结果：预计在10年内（2014-2023年），肺炎球菌病将在10年内（2014-2023年）影响5岁以下的18 713 211名儿童（519 412肺炎，18 148 116急性中耳炎，6884脑膜炎和38 799非肺炎，非脑膜炎）。使用疫苗。引入PCV-13可预防4 900 084例肺炎球菌疾病（190 849肺炎，4 692 450急性中耳炎，2529脑膜炎和14 256非肺炎，非脑膜炎）。肺炎球菌感染将导致287 950例住院和29 399例死亡。接种疫苗可避免105802例住院和9997例死亡。政府和社会每增加一个DALY的成本效益估计分别为1890美元和1538美元。结论：根据世卫组织建议的解释成本效益的阈值，在伊朗伊斯兰共和国为5岁以下儿童引入PCV-13会具有成本效益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号